South Dakota Investment Council Purchases 30,611 Shares of IQVIA Holdings Inc. $IQV

South Dakota Investment Council lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 33.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 122,152 shares of the medical research company’s stock after purchasing an additional 30,611 shares during the quarter. South Dakota Investment Council’s holdings in IQVIA were worth $20,832,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of IQV. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA in the fourth quarter worth approximately $25,000. Financial Freedom LLC bought a new position in IQVIA during the first quarter valued at approximately $25,000. Ascentis Independent Advisors purchased a new position in shares of IQVIA during the first quarter worth approximately $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $27,000. Finally, Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at $27,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on IQV. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. HSBC reaffirmed a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Morgan Stanley restated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Mizuho lifted their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Evercore reiterated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Thirteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

Trending Headlines about IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Second-quarter results exceeded expectations: IQVIA reported adjusted earnings of $3.15 per share versus the $3.03 consensus estimate, while revenue rose 8.7% year over year to $4.37 billion, above expectations of $4.30 billion. IQVIA Reports Second-Quarter 2026 Results
• Positive Sentiment: Full-year guidance was raised: IQVIA now expects fiscal 2026 earnings of $12.80 to $13.00 per share, above the prior consensus estimate of $12.57. Revenue guidance of $17.3 billion to $17.5 billion also reflects continued expansion in the business. IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
• Positive Sentiment: Demand indicators improved: Record R&D bookings, broad-based growth and a ballooning backlog suggest strong future revenue visibility and sustained demand for IQVIA’s clinical-research and healthcare-intelligence services. IQVIA Stocks Rises on 2Q Gains, Ballooning Backlog
• Positive Sentiment: Analysts became more bullish: JPMorgan raised its price target from $225 to $285 and assigned an “overweight” rating. Stifel lifted its target from $220 to $276 with a “buy” rating, while Robert W. Baird increased its target from $252 to $287 and maintained an “outperform” rating. These revisions indicate that analysts view the earnings beat and stronger outlook as durable catalysts.
• Neutral Sentiment: IQVIA’s new simplified organizational model is intended to improve collaboration and efficiency, but the financial benefits will depend on execution over time. The stock is also trading near its 52-week high, leaving less room for disappointment if growth or guidance momentum slows.

IQVIA Price Performance

IQV stock opened at $247.84 on Thursday. The stock has a market capitalization of $41.36 billion, a price-to-earnings ratio of 30.75, a PEG ratio of 2.18 and a beta of 1.20. The firm’s 50-day moving average price is $192.00 and its two-hundred day moving average price is $186.89. The company has a current ratio of 0.71, a quick ratio of 0.75 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has authorized a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.